The trade balance calculation might take some doing, but United Kingdom-based Shire is building new manufacturing facilities in the United States and some of the first drugs to spill from one of the new facilities will go back to Europe.
Shire's new manufacturing facility in Lexington, Mass., will help the pharmaceutical company to the produce the drug Vpriv (velaglucerase alfa), which helps treat Gaucher disease and which was just approved by the European Medicines Agency's Committee for Medical Products for Human Use. The European Commission probably will approve shortly.
Gaucher disease is a rare, chronic, progressive, inherited genetic disorder involving the lack sufficient levels of a particular enzyme. A fatty material, or lipid, accumulates in the body. The accumulation in organs and bones can cause pain throughout life.
Shire is based in Basingstoke, about halfway between London and Southampton in the United Kingdom, but its U.S. headquarters is in Wayne.